AlphaValue Corporate Services
Cette analyse a été commandée et financée par l’entreprise concernée et constitue donc un avantage non-monétaire mineur tel que défini par MIFID2

Crossject

CR
Bloomberg   ALCJ FP
Super Génériques  /  France  Web Site   |   Investors Relation
Things get moving
Objectif
Potentiel 121 %
Cours (€) 4,37
Capi (M€) 159
A Savoir

Zeneo, an automatic, single-use needle-free injection device was originally developed within Laboratoires Fournier in its « drug delivery » division, together with SNPE (Société Nationale des Poudres et Explosifs, which is a shareholder of Crossject). In 2001, the technology was sold to the newly-created Crossject. GSK was originally the main partner of Crossject, with a view to developing a solution for its vaccines. This market was ultimately considered as too risky in terms of investment needs, low margins and the high volumes required and so Crossject was restructured in 2011-13, with a change in the group’s strategy: the goal of Crossject is no longer to sell a device to the Big Pharmas to market their own chemical entities, but to provide the market with its own pre-filled devices, on the basis of New Therapeutic Entities, using a known drug with an innovative delivery system. An industrial partnership has also been signed with Cenexi in 2016 (aseptic filling and final packaging). Today, the Zeneo device is protected by over 400 patents in countries covering 80% of the global market (including the US, Europe and Japan) and valid until 2036.

Actionnaires
Nom% détenu Dont
droits de votes
Dont
flottant
Gemmes Ventures 24,0 %30,0 %0,00 %
Vester Finance 14,8 %11,0 %14,8 %
SNPE 2,80 %2,80 %0,00 %
Other 2,42 %2,42 %0,00 %
IDEB 0,65 %0,65 %0,00 %
Treasury Shares 0,65 %0,65 %0,00 %
Flottant  69,5 %
Changement de l'actionnariat : 07/10/2022.
Concepts
Concept d'activité
  • Entreprises dépendantes des gouver...
Concept d'investissement
  • Entreprise de croissance